nach oben

Breast Cancer Research

Erschienen in:

01.04.2012 | Viewpoint

BRCA1 as tumor suppressor: lord without its RING?

verfasst von: Andrew EH Elia, Stephen J Elledge

Erschienen in: Breast Cancer Research | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

BRCA1 is a tumor suppressor with critical roles in the maintenance of genomic stability. It encodes a large protein with an amino-terminal RING domain that possesses ubiquitin-ligase activity. Given the occurrence of numerous cancer-causing mutations within its RING domain, investigators have long suspected that BRCA1's ubiquitin ligase is important for its tumor suppression and DNA repair activities. Using genetically engineered mouse models, two recent studies shed light on this age-old hypothesis.

Nur mit Berechtigung zugänglich

Huen MS, Sy SM, Chen J: BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol. 2010, 11: 138-148. 10.1038/nrm2831.CrossRefPubMed

Manke IA, Lowery DM, Nguyen A, Yaffe MB: BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science. 2003, 302: 636-639. 10.1126/science.1088877.CrossRefPubMed

Yu X, Chini CC, He M, Mer G, Chen J: The BRCT domain is a phospho-protein binding domain. Science. 2003, 302: 639-642. 10.1126/science.1088753.CrossRefPubMed

Brzovic PS, Keeffe JR, Nishikawa H, Miyamoto K, Fox D 3rd, Fukuda M, Ohta T, Klevit R: Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex. Proc Natl Acad Sci USA. 2003, 100: 5646-5651. 10.1073/pnas.0836054100.CrossRefPubMedPubMedCentral

Shakya R, Reid LJ, Reczek CR, Cole F, Egli D, Lin CS, deRooij DG, Hirsch S, Ravi K, Hicks JB, Szabolcs M, Jasin M, Baer R, Ludwig T: BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity. Science. 2011, 334: 525-528. 10.1126/science.1209909.CrossRefPubMedPubMedCentral

Drost R, Bouwman P, Rottenberg S, Boon U, Schut E, Klarenbeek S, Klijn C, van der Heijden I, van der Gulden H, Wientjens E, Pieterse M, Catteau A, Green P, Solomon E, Morris JR, Jonkers J: BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell. 2011, 20: 797-809. 10.1016/j.ccr.2011.11.014.CrossRefPubMed

Christensen DE, Brzovic PS, Klevit RE: E2-BRCA1 RING interactions dictate synthesis of mono- or specific polyubiquitin chain linkages. Nat Struct Mol Biol. 2007, 14: 941-948. 10.1038/nsmb1295.CrossRefPubMed

Reid LJ, Shakya R, Modi AP, Lokshin M, Cheng JT, Jasin M, Baer R, Ludwig T: E3 ligase activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of double-strand DNA breaks. Proc Natl Acad Sci USA. 2008, 105: 20876-20881. 10.1073/pnas.0811203106.CrossRefPubMedPubMedCentral

Clapperton JA, Manke IA, Lowery DM, Ho T, Haire LF, Yaffe MB, Smerdon SJ: Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer. Nat Struct Mol Biol. 2004, 11: 512-518. 10.1038/nsmb775.CrossRefPubMed

10.

Morris JR, Solomon E: BRCA1:BARD1 induces the formation of conjugated ubiquitin structures, dependent on K6 of ubiquitin, in cells during DNA replication and repair. Hum Mol Genet. 2004, 13: 807-817. 10.1093/hmg/ddh095.CrossRefPubMed

11.

Polanowska J, Martin JS, Garcia-Muse T, Petalcorin MI, Boulton SJ: A conserved pathway to activate BRCA1-dependent ubiquitylation at DNA damage sites. EMBO J. 2006, 25: 2178-2188. 10.1038/sj.emboj.7601102.CrossRefPubMedPubMedCentral

12.

Zhao GY, Sonoda E, Barber LJ, Oka H, Murakawa Y, Yamada K, Ikura T, Wang X, Kobayashi M, Yamamoto K, Boulton SJ, Takeda S: A critical role for the ubiquitin-conjugating enzyme Ubc13 in initiating homologous recombination. Mol Cell. 2007, 25: 663-675. 10.1016/j.molcel.2007.01.029.CrossRefPubMed

13.

Ye Y, Rape M: Building ubiquitin chains: E2 enzymes at work. Nat Rev Mol Cell Biol. 2009, 10: 755-764. 10.1038/nrm2780.CrossRefPubMedPubMedCentral

14.

Christensen DE, Klevit RE: Dynamic interactions of proteins in complex networks: identifying the complete set of interacting E2s for functional investigation of E3-dependent protein ubiquitination. FEBS J. 2009, 276: 5381-5389. 10.1111/j.1742-4658.2009.07249.x.CrossRefPubMedPubMedCentral

15.

Zhu Q, Pao GM, Huynh AM, Suh H, Tonnu N, Nederlof PM, Gage FH, Verma IM: BRCA1 tumour suppression occurs via heterochromatin-mediated silencing. Nature. 2011, 477: 179-184. 10.1038/nature10371.CrossRefPubMedPubMedCentral

Titel: BRCA1 as tumor suppressor: lord without its RING?
verfasst von: Andrew EH Elia
Stephen J Elledge
Publikationsdatum: 01.04.2012
Verlag: BioMed Central
Erschienen in: Breast Cancer Research / Ausgabe 2/2012
Elektronische ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr3118

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

BRCA1 as tumor suppressor: lord without its RING?

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Advances in molecular imaging for breast cancer detection and characterization

CIP2A is a target of bortezomib in human triple negative breast cancer cells

In vivo proton magnetic resonance spectroscopy of breast cancer: a review of the literature

Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression

Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice

Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie